| Literature DB >> 31998702 |
Ilaria Raimondi1, Luca Izzo1, Marta Tunesi1, Manola Comar2, Diego Albani3, Carmen Giordano1.
Abstract
We are accumulating evidence that intestinal microflora, collectively named gut microbiota, can alter brain pathophysiology, but researchers have just begun to discover the mechanisms of this bidirectional connection (often referred to as microbiota-gut-brain axis, MGBA). The most noticeable hypothesis for a pathological action of gut microbiota on the brain is based on microbial release of soluble neurotransmitters, hormones, immune molecules and neuroactive metabolites, but this complex scenario requires reliable and controllable tools for its causal demonstration. Thanks to three-dimensional (3D) cultures and microfluidics, engineered in vitro models could improve the scientific knowledge in this field, also from a therapeutic perspective. This review briefly retraces the main discoveries linking the activity of gut microbiota to prevalent brain neurodegenerative disorders, and then provides a deep insight into the state-of-the-art for in vitro modeling of the brain and the blood-brain barrier (BBB), two key players of the MGBA. Several brain and BBB microfluidic devices have already been developed to implement organ-on-a-chip solutions, but some limitations still exist. Future developments of organ-on-a-chip tools to model the MGBA will require an interdisciplinary approach and the synergy with cutting-edge technologies (for instance, bioprinting) to achieve multi-organ platforms and support basic research, also for the development of new therapies against neurodegenerative diseases.Entities:
Keywords: blood-brain barrier; brain; in vitro modeling; microbiota-gut-brain axis; microfluidics; neurodegenerative diseases
Year: 2020 PMID: 31998702 PMCID: PMC6965718 DOI: 10.3389/fbioe.2019.00435
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Bacteria release neuromodulators.
| 5-Hydroxytryptamine | anxiety, depression, MS, PD | Baganz and Blakely, | |
| β-Methylamino-L-alanine (BMAA) | AD, ALS, PD | Meneely et al., | |
| γ-Aminobutyric (GABA) | AD, anxiety, depression | Barrett et al., | |
| Acetylcholine | AD | Wessler and Kirkpatrick, | |
| Catecholamine (Adrenaline, Dopamine, Noradrenaline) | ASD, depression, PD, schizophrenia | Mayer and Hsiao, | |
| Histamine | AD, MS | Landete et al., | |
| Lipopolysaccharide (LPS) | AD, anxiety, ASD depression, HD, MS, PD, schizophrenia, etc. | Zhao et al., | |
| Short-chain fatty acids (SCFA, e.g., acetate, propionate and butyrate) | AD, ASD, HD, PD | Liu et al., | |
| Gingipains | AD, PD | Adams et al., |
Summary of the most important neuropeptides involved in brain disorders such as anxiety, autism, AD, amyotrophic lateral sclerosis, depression, MS, schizophrenia, and PD.
In vitro models of the BBB, 2D condition.
| Primary mouse BCEC + astrocytes | co-culture | – | occludins, | TEER 800 | Coisne et al., |
| Primary rat BCEC + astrocytes | co-culture | AD, encephalitis, | occludins, | TEER 300–600 | Nakagawa et al., |
| Primary rat BCEC + astrocytes + pericytes | co-culture | AD | occludins, | TEER 350–723 | Nakagawa et al., |
| Primary rat BCEC + astrocytes + neurons | co-culture | AD, epilepsy | occludins, | TEER 268 | Xue et al., |
| Primary bovine BCEC + rat astrocytes | co-culture | – | Occludins | TEER 600–800 | Gaillard et al., |
| Primary bovine BCEC (clonal selection) + | co-culture | – | occludins, | TEER 800 | Dehouck et al., |
| Primary porcine BCEC + rat astrocytes or astrocyte cell line | co-culture | AD, HD | occludins, | TEER 800–1,800 | Cohen-Kashi Malina et al., |
They are based on primary or immortalized cells.
AD, Alzheimer's disease; BCEC, brain capillary endothelial cells; HD, Huntington's disease; MS, multiple sclerosis; P.
In vitro models of the BBB, 2D condition.
| hPSC + rat astrocytes | co-culture | AD, MS and brain tumors | occludins, | TEER 700 | Lippmann et al., |
| hPSC + pericyte-primed human NPC | co-culture | occludins, | TEER 5350 | Lippmann et al., | |
| Cord blood-derived endothelial progenitor cells + pericytes | co-culture | AD, MS | occludins, | TEER 160 | Cecchelli et al., |
| hIPS-EC + hIPS-NSC + astrocytes + pericytes | co-culture | AD, PD | occludins, | TEER 433–2,489 | Appelt-Menzel et al., |
They are based on human-induced pluripotent stem (hIPS) cells or progenitor cells.
AD, Alzheimer's disease; hIPS-EC, human-induced pluripotent stem cell-derived BBB endothelial cells; hPSC, human pluripotent stem cells; MS, multiple sclerosis; NPC, neural progenitor cells; NSC, neural stem cells; PD, Parkinson's disease; P.
Figure 1(A) Sketch showing the main organs involved in the microbiota-gut-brain axis and their bidirectional communication; (B) Sketch detailing the biological structures involved in the microbiota-gut-brain axis. From bottom to top: the microbiota resides in the intestinal lumen and in the loose layer of the intestinal mucus. It interplays with the epithelial cells in the gut epithelium, the cells of the immune system circulating into the bloodstream, the blood-brain barrier (BBB) composed of endothelial cells (EC), pericytes and astrocytic end-feet processes and brain cells (e.g., neurons, microglia, astrocytes, and oligodendrocytes); (C) Sketch of the MINERVA organ-on-a-chip platform. From bottom to top: the microbiota-on-a-chip device hosts a microporous membrane supporting a hydrogel-based matrix mimicking gut mucus and inoculated with gut microbiota; the gut-on-a-chip device hosts a microporous membrane seeded with gut epithelial cells (e.g., CaCo-2 cells); the immune system-on-a-chip device hosts macrophages and lymphocytes; the BBB-on-a-chip device hosts two specular monolayers of EC and astrocytes; the brain-on-a-chip device hosts a 3D hydrogel matrix mimicking brain extracellular matrix (ECM) and embedding neurons, microglia and astrocytes. In the MINERVA platform, we have considered two configurations for the brain-on-a-chip device: the first is composed of three chambers hosting the co-culture of neurons, microglia and astrocytes, while the second has three chambers hosting neurons, microglia and astrocytes as a single culture. Both the microbiota and the immune system compartments have filters at the inlet and outlet to prevent cell migrating out from the culture chambers. With the exception of the brain device, each compartment has a microporous membrane to support cell adhesion. It also allows the passage of secretome to the lower part of the culture chamber without mixing of the different culture media. Created with BioRender.com.